产品说明书

Maribavir

Print
Chemical Structure| 176161-24-3 同义名 : GW257406X;1263W94;VP-41263;SHP-620;GW-1263;BW1263W94
CAS号 : 176161-24-3
货号 : A851897
分子式 : C15H19Cl2N3O4
纯度 : 99%+
分子量 : 376.235
MDL号 : MFCD00945570
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 190 mg/mL(505 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Maribavir effectively inhibits the autophosphorylation of both wild-type and major Ganciclovir (GCV) resistant UL97 mutants, with an average IC50 of 35 nM. The M460I mutation exhibits increased sensitivity to Maribavir, having an IC50 of 4.8 nM, while the Maribavir-resistant UL97 mutant L397R shows reduced kinase activity to about 10% of the wild type. Enzyme kinetics reveal Maribavir acts as a competitive inhibitor of ATP with a Ki of 10 nM[1]. Additionally, Maribavir suppresses viral replication dose-dependently with an IC50 of 0.12±0.01 μM in multicycle DNA hybridization assays, and strongly inhibits the pUL97 protein kinase at a 50% inhibition concentration of 3 nM[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00002373 Cytomegalovirus Infections ... 展开 >> HIV Infections 收起 << Phase 1 Completed - United States, California ... 展开 >> Univ of California/ San Francisco / Dept of Medicine San Francisco, California, United States, 94110 Dr Jacob Lalezari San Francisco, California, United States, 94115 收起 <<
NCT00411645 Cytomegalovirus Infections Phase 3 Completed - -
NCT00497796 Cytomegalovirus Infections Phase 3 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.29mL

2.66mL

1.33mL

26.58mL

5.32mL

2.66mL
参考文献

[1]Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4.

[2]Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.